DOCSLIB.ORG

Transplant Immunology.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transplant Immunology.Pdf POLICY BRIEFING Transplant Immunology September 2017 The British Society of Immunology is the largest Introduction immunology society in Europe. Our mission is to promote excellence in immunological research, scholarship and Transplantation is the process of moving cells, tissues, or clinical practice in order to improve human and animal organs, from one site to another, either within the same health. We represent the interests of more than 3,000 person or between a donor and a recipient. If an organ immunologists working in academia, clinical medicine, system fails, or becomes damaged as a consequence of and industry. We have strong international links and disease or injury, it can be replaced with a healthy organ collaborate with our European, American and Asian or tissue from a donor. partner societies in order to achieve our aims. Organ transplantation is a major operation and is only Key points: offered when all other treatment options have failed. Consequently, it is often a life-saving intervention. In • Transplantation is the process of moving cells, 2015/16, 4,601 patient lives were saved or improved in i tissues or organs from one site to another for the the UK by an organ transplant. Kidney transplants are purpose of replacing or repairing damaged or the most common organ transplanted on the NHS in diseased organs and tissues. It saves thousands the UK (3,265 in 2015/16), followed by the liver (925), and i of lives each year. However, the immune system pancreas (230). In addition, a total of 383 combined heart poses a significant barrier to successful organ and lung transplants were performed, while in 2015/16. transplantation when tissues/organs are trans- However, whole organs are not the only type of transplant. ferred from one individual to another. The cornea, for example, is the most transplanted single tissue, with 5,734 procedures carried out in 2015/16.i • Rejection is caused by the immune system Hematopoietic stem cell transplantation (HSCT), often identifying the transplant as foreign, triggering a called blood and marrow transplantation (BMT), is another response that will ultimately destroy the trans- common tissue transplantation procedure. Used to treat planted organ or tissue. Long term survival of the a broad spectrum of diseases, though most commonly transplant can be maintained by manipulating the for blood or bone marrow cancers such as leukaemia immune system to reduce the risk of rejection. and lymphoma, around 3,600 HSCT transplants were undertaken in 2012. • Donor and recipient are carefully matched prior to transplantation to minimise the risk of rejection. The immune system plays a critical role in They are matched based on their blood group, transplantation. The complex mechanisms of immunity, tissue typing, and how the recipient’s blood serum which under normal circumstances work to identify reacts to donor cells. foreign microbes and direct the immune system to destroy them, pose a significant barrier to successful • Immunosuppressive drugs are used to prevent transplantation. Rejection of a transplant occurs in and to treat transplant rejection by dampening the instances where the immune system identifies the overall immune response. However, immunosup- transplant as foreign, triggering a response that will pressive drugs are non-specific and leave patients ultimately destroy the transplanted organ or tissue. more susceptible to disease as well as being associated with numerous unwanted side effects. The intensity of the immune response against the organ or tissue, also commonly referred to as the graft, will • Further research on the immunological mecha- depend on the type of graft being transplanted and the nisms of rejection will help improve cross match- genetic disparity between the donor and recipient. To ing, diagnosis and treatment, as well as facilitat- reduce the possibility of rejection, the donor and recipient ing the discovery of novel strategies for preventing are carefully matched for immune compatibility prior to transplant rejection. transplantation. However, the small pool of eligible donors can make it difficult to find a donor-recipient match and there will always be a degree of rejection against the graft. A critical undersupply of donated organs means that waiting lists for transplants are extremely long. Patients needing a kidney transplantation, for example, wait on British Society for Immunology Julia Deathridge 34 Red Lion Square Intern London, WC1R 4SG Telephone: 020 3019 5911 Email: [email protected] POLICY BRIEFING Transplant Immunology September 2017 average 944 days (more than two and a half years) for a damaged or destroyed blood cells. Haematopoietic life-saving transplant.ii stem cell transplants are used to treat certain types of cancer e.g. leukaemia, and blood diseases where the There were 6,943 patients registered for organ transplant bone marrow has become damaged preventing the in the UK as of March 2015.i Unfortunately, 479 of production of healthy blood cells. These stem cells these patients died during 2015/16 whilst waiting for a can be harvested either directly from bone marrow transplant due the small pool of transplantable organs.i or from the cord blood (blood from the placenta and These figures underline the value of every organ and umbilical cord) from consenting mothers following highlight the importance of a successful transplantation childbirth. and maintaining long-term transplant survival. Manipulation of the immune system can support long- term survival of the graft ensuring that every transplant is The immunology of transplant rejection as successful as possible. Distinguising between self and non-self There are several types of transplantation involving tissues and organs: When the immune system encounters a foreign organism, it mounts an attack against it to protect the body from • Autograft –Transplantation of cells, tissues or organs infection. To prevent an attack on our own cells and between sites within the same individual e.g. skin tissues (autoimmunity), the immune system must be graft. able to differentiate between our own healthy tissues and foreign invaders. • Allograft – Transplantation of organs or tissues from a donor to a non-genetically identical individual of the Foreign invaders are presented to the immune system in same species. Allografts are the most common type the form of small molecules called antigens. Identification of transplant. of these non-self antigens will trigger an immune response and will stimulate the production of antigen- • Xenograft – Transplantation of an organ or tissue specific antibodies that mark infected cells for destruction between two different species. ‘Pig valves’, for by the immune system and help amplify the immune example, are commonly used to repair or replace response. a defective heart valve in humans. In 2015/16, 6,069 xenograft valve replacements were carried out in The Human Leukocyte Antigen (HLA) complex is a England by the NHS.iii Xenotransplantation of whole group of genes that encode the proteins responsible for organs is not currently viable, although it is an area of identifying foreign agents to the immune system. These huge scientific interest as a potential solution for the proteins are found on the surface of all cells and act as existing critical undersupply of adequate organs. ‘self-markers’ telling the immune system not to trigger a response. Each person will have their own specific set of • ABO incompatible – ABO refers to blood group, which HLA proteins, based upon their unique genetic make-up, can vary between individuals. For most transplant that the immune system will have learned not to react to. types, matching of blood group between donor and Any cell not displaying these specific HLA proteins will be recipient is a key strategy in reducing rejection risk. identified as ‘non-self’ by the immune system and will be However, blood group compatibility is not always treated as a foreign invader. required for transplantations. For example, in the case of very young children with immature immune Mechanism of rejection systems, ABO incompatible transplants can be carried out with less risk of transplant rejection. Graft rejection occurs when the recipient’s immune system attacks the donated graft and begins destroying • Stem cell transplant – Stem cells are cells that have the transplanted tissue or organ. The immune response the capacity to develop into a range of different types is usually triggered by the presence of the donor’s own of cells in the body. Blood stem cells (haematopoietic unique set of HLA proteins, which the recipient’s immune stem cells) can develop into all the different cells system will identify as foreign. found in the blood and are donated to replace British Society for Immunology Julia Deathridge 34 Red Lion Square Intern London, WC1R 4SG Telephone: 020 3019 5911 Email: [email protected] POLICY BRIEFING Transplant Immunology September 2017 The degree of similarity between the HLA genes of the Chronic rejection donor and recipient is known as histocompatibility; the more genetically compatible the donor and the recipient, Repeated episodes of acute rejection can ultimately the more tolerant the recipient’s immune system should lead to chronic rejection of the graft and failure of the be of the graft. However, unless the donor and recipient transplant. Chronic rejection commonly manifests as are genetically identical (e.g. as in identical twins) there scarring of the tissue or organ which can occur months to will always be some degree of rejection. As well as non- years after acute rejection has subsided. At present, there self HLA proteins, other surface proteins on the donor is no cure for chronic rejection other than removal of the graft can also be identified as a foreign antigen and illicit graft. an immune response. Finding an eligible donor-recipient match In some cases, a patient may experience something known as ‘graft versus host reaction’ where mature Rejection can be minimised by carefully matching immune cells already present in the donor graft begin the donor and recipient for compatibility prior to attacking the healthy cells of the recipient.
Load more

Recommended publications
  • 9. Types of Rejection Table of Contents 9.1 Antibody-Mediated Rejection
    9. Types of rejection Table of Contents 9.1 Antibody-mediated rejection 9.2 Chronic rejection 9.3 Hyperacute rejection 9.4 T-cell mediated rejection 9.5 Donor specific cell free DNA marker 9.1 Antibody-mediated rejection The 2019 Expert Consensus from the Transplantation Society Working Group (2020). Recommended Treatment for Antibody-mediated Rejection after Kidney Transplantation. Transplantation. 2020 Jan 8. doi: 10.1097/TP.0000000000003095. [Epub ahead of print]. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/31895348 • A consensus of expert opinion in regards to standard of care treatment for active and chronic active AMR after kidney transplantation Yamanashi K, Chen-Yoshikawa TF, Hamaji M, et al (2020). Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. Gen Thorac Cardiovasc Surg. 2020;68(2):142–149. doi:10.1007/s11748-019-01189-1. Retrieved from: https://europepmc.org/article/med/31435872 • This study is a retrospective analysis of a single center’s experience of using combination therapy (methylprednisolone, plasma exchange, and IVIG) including rituximab for post lung transplant AMR in Japanese patients. Spica D, Junker T, Dickenmann M, et al (2019). Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Rep Nephrol Dial. 2019;9(3):149–157. Published 2019 Nov 13. doi:10.1159/000503951. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902247/ • A case report detailing the use of Daratnumumab for treatment of therapy-refractory AMR in the context of ABO-incompatible kidney transplantation. Kincaide E, Hitchman K, Hall R, Yamaguchi I, Ding Y, Crowther B (2019).
    [Show full text]
  • Organ Transplant Discrimination Against People with Disabilities Part of the Bioethics and Disability Series
    Organ Transplant Discrimination Against People with Disabilities Part of the Bioethics and Disability Series National Council on Disability September 25, 2019 National Council on Disability (NCD) 1331 F Street NW, Suite 850 Washington, DC 20004 Organ Transplant Discrimination Against People with Disabilities: Part of the Bioethics and Disability Series National Council on Disability, September 25, 2019 This report is also available in alternative formats. Please visit the National Council on Disability (NCD) website (www.ncd.gov) or contact NCD to request an alternative format using the following information: [email protected] Email 202-272-2004 Voice 202-272-2022 Fax The views contained in this report do not necessarily represent those of the Administration, as this and all NCD documents are not subject to the A-19 Executive Branch review process. National Council on Disability An independent federal agency making recommendations to the President and Congress to enhance the quality of life for all Americans with disabilities and their families. Letter of Transmittal September 25, 2019 The President The White House Washington, DC 20500 Dear Mr. President, On behalf of the National Council on Disability (NCD), I am pleased to submit Organ Transplants and Discrimination Against People with Disabilities, part of a five-report series on the intersection of disability and bioethics. This report, and the others in the series, focuses on how the historical and continued devaluation of the lives of people with disabilities by the medical community, legislators, researchers, and even health economists, perpetuates unequal access to medical care, including life- saving care. Organ transplants save lives. But for far too long, people with disabilities have been denied organ transplants as a result of unfounded assumptions about their quality of life and misconceptions about their ability to comply with post-operative care.
    [Show full text]
  • Chronic Rejection Autoimmunity
    Antibodies to MHC Class I Induce Autoimmunity: Role in the Pathogenesis of Chronic Rejection This information is current as Naohiko Fukami, Sabarinathan Ramachandran, Deepti Saini, of September 26, 2021. Michael Walter, William Chapman, G. Alexander Patterson and Thalachallour Mohanakumar J Immunol 2009; 182:309-318; ; doi: 10.4049/jimmunol.182.1.309 http://www.jimmunol.org/content/182/1/309 Downloaded from References This article cites 54 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/182/1/309.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Antibodies to MHC Class I Induce Autoimmunity: Role in the Pathogenesis of Chronic Rejection1 Naohiko Fukami,* Sabarinathan Ramachandran,* Deepti Saini,* Michael Walter,‡ William Chapman,* G. Alexander Patterson,§ and Thalachallour Mohanakumar2*† Alloimmunity to mismatched donor HLA-Ags and autoimmunity to self-Ags have been hypothesized to play an important role in immunopathogenesis of chronic rejection of transplanted organs.
    [Show full text]
  • Organ Donation Opportunites for Action
    http://www.nap.edu/catalog/11643.html We ship printed books within 1 business day; personal PDFs are available immediately. Organ Donation: Opportunities for Action Committee on Increasing Rates of Organ Donation, James F. Childress and Catharyn T. Liverman, Editors ISBN: 0-309-65733-4, 358 pages, 6 x 9, (2006) This PDF is available from the National Academies Press at: http://www.nap.edu/catalog/11643.html Visit the National Academies Press online, the authoritative source for all books from the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the National Research Council: • Download hundreds of free books in PDF • Read thousands of books online for free • Explore our innovative research tools – try the “Research Dashboard” now! • Sign up to be notified when new books are published • Purchase printed books and selected PDF files Thank you for downloading this PDF. If you have comments, questions or just want more information about the books published by the National Academies Press, you may contact our customer service department toll- free at 888-624-8373, visit us online, or send an email to [email protected]. This book plus thousands more are available at http://www.nap.edu. Copyright © National Academy of Sciences. All rights reserved. Unless otherwise indicated, all materials in this PDF File are copyrighted by the National Academy of Sciences. Distribution, posting, or copying is strictly prohibited without written permission of the National Academies Press. Request reprint permission for this book. Organ Donation: Opportunities for Action http://www.nap.edu/catalog/11643.html ORGAN DONATION OPPORTUNITIES FOR ACTION Committee on Increasing Rates of Organ Donation Board on Health Sciences Policy James F.
    [Show full text]
  • Organ and Tissue Donation
    ORGAN AND TISSUE DONATION www.kidney.org If I needed a kidney or some other vital organ to live… would I be able to get one? Maybe. Some people who need organ transplants cannot get them because of a shortage of donations. The national waiting list for organ transplants grows longer every day. Thousands die each year while waiting for a transplant of a vital organ, such as a kidney, heart, or liver. How are organs and tissues for transplantation obtained? Organs can be donated by people at the time of death (deceased donors) or by living donors. A living donor may be a relative, friend, or possibly someone who does not know the recipient but wishes to be a donor for someone in need. This brochure provides information about organ and tissue donation at the time of death. For more information about living donation, visit www.kidney.org/livingdonors How are donated organs and tissues distributed? The federal government contracts with an independent organization, called 2 NATIONAL KIDNEY FOUNDATION the United Network for Organ Sharing (UNOS), to manage the distribution of organs donated by individuals at the time of death (deceased donors). Because of the shortage of donations, transplant candidates’ names are placed on a waiting list. Guidelines have been established to ensure that all patients on the waiting list have a fair chance at receiving the organ they need regardless of age, sex, race, lifestyle, or social status. Organs are also distributed based on needs and medical criteria. Donated tissues are distributed through a separate process, which is coordinated by various tissue banks.
    [Show full text]
  • Hypersensitivity Reactions Corenotes by Core Concepts Anesthesia Review, LLC
    Hypersensitivity Reactions CoreNotes by Core Concepts Anesthesia Review, LLC 1. There are 4 types of hypersensitivity reactions. 2. Type 1 reactions are immediate-type reactions, including anaphylaxis. Signs & symptoms are the result of the release of histamine and other autocoids from mast cells & basophils. 3. Type 2 reactions are cytotoxic reactions and are cell mediated. ABO- incompatibility reactions are of this type. 4. Type 3 reactions are the result of soluble antigens and antibodies combining to form insoluble complexes. Neutrophils are activated and tissue damage results. Serum sickness and Arthus reactions are examples of Type 3 reactions 5. Type 4 reactions are also known as delayed hypersensitivity reactions. These are the result of antigens reacting with sensitized lymphocytes. Contact dermatitis is an example of a Type 4 reaction Type 1 hypersensitivity reactions involve the combination of antigen with circulating IgE. This produces degranulation of basophils and mast cells with the release of histamine and other autocoids. Type 1 reactions require previous exposure to the antigen, thereby causing the production of the IgE. Type 2 hypersensitivity reactions are antibody dependent, cell-mediated reactions. These reactions are mediated through IgG or IgM antibodies directed against cellular surface antigens. Previous exposure, as in ABO-incompatibility reactions, is not required. Cell damage from type 2 reactions is the result of cell lysis with complement activation and subsequent phagocytosis. Type 3 hypersensitivity reactions are also known as immune-complex reactions. These reactions result from soluble antigens and antibodies combining to form insoluble complexes, which deposit in the microvasculature. The subsequent inflammatory process then produces tissue damage.
    [Show full text]
  • AUTOIMMUNITY Transplant Rejection AIDS
    AUTOIMMUNITY Transplant rejection AIDS P. Babál ÚPA LFUK AUTOIMMUNITY Allergy - reaction to an allergen from the environment Autoimmunity- immune mechanisms oriented against components of self tissues Ehrlich: “horror autotoxicus” - reparative processes - frequently accompanied by antibodies against altered tissues (faster removal of these tissues) - if autoantibodies persist permanently -> autoimmunity - organ specific - systemic MECHANISMS BY WHICH AUTOIMMUNITY DEVELOPS Release of sequestered Ag - spermatozoa, lens, myelin Abnormal T-cell function: - Systemic lupus erythematodes, diminished Ts function other AI diseases Enhanced Th cell function - hemolytic anemias Polyclonal B cell activation - SLE, EBV-induced anti-DNA Ab GENETIC FACTORS in autoimmunity HLA system of genes - regulates immune responses = individuals with certain HLA genes expression are at higher risk to develop AI disease Ankylotic spondyllitis B27 87.4 % Autoimmune thyreotoxicosis DR3 3.7 Hashimoto thyroiditis DR5 3.2 Diabetes mellitus II. DR3 3.3 Sclerosis multiplex DR2 4.1 Goodpasture sy. DR2 15.9 Autoimmune diseases of NERVE SYSTEM Systemic polyradiculoneuropathy (Guillain-Barre sy.) - 3/4 weeks after viral infection = demyelinization of motor neurons … anti-myelin Ab Myastenia gravis autoAb reacting with receptors for ACH at the neuro-muscular disc (block, destruction) -> weakness. Result of Ts failure to suppress autoimmune B-cell clones Acute allergic encephalomyelitis - 2 weeks after viral infection, usually measles (morbilli) typical perivascular demyelinization
    [Show full text]
  • B Cell Immunity in Solid Organ Transplantation
    REVIEW published: 10 January 2017 doi: 10.3389/fimmu.2016.00686 B Cell Immunity in Solid Organ Transplantation Gonca E. Karahan, Frans H. J. Claas and Sebastiaan Heidt* Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands The contribution of B cells to alloimmune responses is gradually being understood in more detail. We now know that B cells can perpetuate alloimmune responses in multiple ways: (i) differentiation into antibody-producing plasma cells; (ii) sustaining long-term humoral immune memory; (iii) serving as antigen-presenting cells; (iv) organizing the formation of tertiary lymphoid organs; and (v) secreting pro- as well as anti-inflammatory cytokines. The cross-talk between B cells and T cells in the course of immune responses forms the basis of these diverse functions. In the setting of organ transplantation, focus has gradually shifted from T cells to B cells, with an increased notion that B cells are more than mere precursors of antibody-producing plasma cells. In this review, we discuss the various roles of B cells in the generation of alloimmune responses beyond antibody production, as well as possibilities to specifically interfere with B cell activation. Keywords: HLA, donor-specific antibodies, antigen presentation, cognate T–B interactions, memory B cells, rejection Edited by: Narinder K. Mehra, INTRODUCTION All India Institute of Medical Sciences, India In the setting of organ transplantation, B cells are primarily known for their ability to differentiate Reviewed by: into long-lived plasma cells producing high affinity, class-switched alloantibodies. The detrimental Anat R. Tambur, role of pre-existing donor-reactive antibodies at time of transplantation was already described in Northwestern University, USA the 60s of the previous century in the form of hyperacute rejection (1).
    [Show full text]
  • Immune Globulins (Immunoglobulin): Asceniv; Bivigam; Carimune NF
    Immune Globulins (immunoglobulin): Asceniv; Bivigam; Carimune NF; Flebogamma; Gamunex-C; Gammagard Liquid; Gammagard S/D; Gammaked; Gammaplex; Octagam; Privigen; Panzyga (Intravenous) Document Number: IC-0071 Last Review Date: 10/01/2020 Date of Origin: 07/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 06/2011, 09/2011, 10/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 05/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 06/2015, 09/2015, 12/2015, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 09/2018, 10/2018, 05/2019, 10/2019, 10/2020 I. Length of Authorization Initial and renewal authorization periods vary by specific covered indication. Unless otherwise specified, the initial authorization will be provided for 6 months and may be renewed annually. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC unit]: # of vials Drug Vial size in IgG grams One time only per 28 days LOAD MAINTENANCE Asceniv 5 18 18 5 1 1 Bivigam 10 23 23 3,6 1 1 Carimune NF 12 19 19 5, 10, 20 1 1 Flebogamma 10% DIF 20 11 11 2.5, 5, 10 1 1 Flebogamma 5% DIF 20 11 11 1, 2.5, 5, 10, 20 1 1 Gamunex-C 40 6 6 1, 2.5, 5, 10, 20 1 1 Gammagard Liquid 30 8 8 Proprietary & Confidential © 2020 Magellan Health, Inc. 5 1 1 Gammagard S/D 10 23 23 1, 2.5, 5, 10 1 1 Gammaked 20 11 11 2.5, 5, 10 1 1 Gammaplex 20 11 11 2, 5, 10 1 1 Octagam 10% 20 11 11 1, 2.5, 5, 10 1 1 Octagam 5% 25 9 9 5, 10, 20 1 1 Privigen 40 6 6 Panzyga 1, 2.5, 5, 10, 20 1 1 30 8 8 B.
    [Show full text]
  • "Graft Rejection: Immunological Suppression"
    Graft Rejection: Advanced article Immunological Article Contents . Introduction Suppression . Role of Tissue Typing . Immunosuppressive Agents . Reducing Immunogenicity of Grafts Behdad Afzali, King’s College London, London, UK . Induction of Transplantation Tolerance Robert Lechler, King’s College London, London, UK Online posting date: 15th September 2010 Giovanna Lombardi, King’s College London, London, UK Based in part on the previous version of this Encyclopedia of Life Sciences (ELS) article, ‘‘Graft Rejection: Immunological Suppression’’ by ‘‘Kathryn J Wood.’’ Transplantation of solid organs is the treatment of choice immune system. Transplantation of cells, tissues or an for most patients with end-stage organ diseases. In the organ between genetically nonidentical individuals (allo- absence of pharmacological immunosuppression, recog- geneic) in the same species or between different species nition of foreign (allogeneic) histocompatibility proteins (xenogeneic) leads to activation of the recipient’s immune expressed on donor cells by the recipient’s immune system system and an immunological reaction against the trans- plant. In this setting, the transplanted tissue(s) (referred to results in rejection of the transplanted tissue(s). One-year as the ‘graft’ – Table 1) is destroyed (rejected) if no further renal transplant survival is now routinely over 90% in intervention is taken. See also: Transplantation most centres, largely the result of improvements in Studies on the behaviour of tumour grafts by Little and immunosuppressive drugs. In this article, we review Tyzzer, among others, led Gorer to propose the concept of commonly used immunosuppressive medications and graft rejection as long ago as 1938. Recognition that the discuss their pharmacological modes of action. Given that immune system was responsible came later when Gibson long-term graft outcomes remain poor despite improve- and Medawar clearly identified specificity and memory as ments in early transplant survival, we discuss, in addition, hallmark features of the rejection response.
    [Show full text]
  • Donor-Derived Cell-Free DNA in Kidney Transplantation As a Potential Rejection Biomarker: a Systematic Literature Review
    Journal of Clinical Medicine Review Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review Adrian Martuszewski 1 , Patrycja Paluszkiewicz 1 , Magdalena Król 2, Mirosław Banasik 1 and Marta Kepinska 3,* 1 Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland; [email protected] (A.M.); [email protected] (P.P.); [email protected] (M.B.) 2 Students Scientific Association, Department of Biomedical and Environmental Analysis, Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] 3 Department of Biomedical and Environmental Analyses, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland * Correspondence: [email protected]; Tel.: +48-71-784-0171 Abstract: Kidney transplantation (KTx) is the best treatment method for end-stage kidney disease. KTx improves the patient’s quality of life and prolongs their survival time; however, not all patients benefit fully from the transplantation procedure. For some patients, a problem is the premature loss of graft function due to immunological or non-immunological factors. Circulating cell-free DNA (cfDNA) is degraded deoxyribonucleic acid fragments that are released into the blood and other body fluids. Donor-derived cell-free DNA (dd-cfDNA) is cfDNA that is exogenous to the patient and comes from a transplanted organ. As opposed to an invasive biopsy, dd-cfDNA can be detected by a non-invasive analysis of a sample. The increase in dd-cfDNA concentration occurs even before the creatinine level starts rising, which may enable early diagnosis of transplant injury and adequate Citation: Martuszewski, A.; treatment to avoid premature graft loss.
    [Show full text]
  • 1 SAMPLE PERSUASIVE SPEECH Title: Organ Donation Specific
    SAMPLE PERSUASIVE SPEECH Title: Organ Donation Specific Purpose: To persuade my audience to donate their organs and tissues when they die and to act upon their decision to donate. Thesis Statement: The need is constantly growing for organ donors and it is very simple to become an organ donor. INTRODUCTION I) How do you feel when you have to wait for something you really, really want? What if it was something you literally couldn’t live without? II) The need is constantly growing for organ donors and it is very simple to become an organ donor. III) Today I’d like to talk to you about the need for organ donors in our area, how organ donor recipients benefit from your donation, and how you can become an organ donor today. IV) I am credible to speak about this topic because I did a lot of research on organ donation and because I am an organ donor myself. (I’ll begin by telling you about the need for organ donors.) BODY I) People around the world and also right here in Minnesota, Wisconsin, Iowa, and Illinois, need organ transplants and they need our help. A) The problem is that there is a lack of organs and organ donors who make organ transplantation possible (Smith 35). B) According to Jane Green and Jim Lee, authors of “Organ Donations in Minnesota,” the number of organ donors in our area has diminished to a low 23% (Green and Lee 23). (Now that you see the great need for organ donors in our area, let’s look at what may happen if you choose to donate your organs.) II) Organ donation benefits both the donor’s family and the recipients.
    [Show full text]